文献速递胃肠外科围术期管理与 ERAS

腹腔镜袖状胃切除术低风险患者三层级低分子肝素剂量方案的长期回顾性安全性有效性分析

Longitudinal retrospective review of three-tiered low molecular weight heparin dosing protocol to prevent thromboembolism in low-risk patients undergoing laparoscopic sleeve gastrectomy.
PubMed 文献 · Surg Endosc · 2025-09-17

该回顾性研究评估了社区医院12年间1936例腹腔镜袖状胃切除术患者采用依诺肝素三层级剂量方案(按体重<300磅、300-400磅、>400磅分别给予30mg、40mg、60mg每12小时一次,术前至少2小时启动)的安全性和有效性。结果显示静脉血栓栓塞发生率为0.21%(4例),出血并发症发生率为0.15%(3例),均低于全国质量数据库报告的平均水平。

要点

  • 依诺肝素三层级剂量方案(按体重分档)在腹腔镜袖状胃切除术中安全有效。
  • VTE发生率0.21%,出血并发症发生率0.15%,均低于全国数据库报告均值。
  • 方案于术前至少2小时启动,每12小时给药一次。

核心结论

  • 本研究所用依诺肝素血栓预防方案安全有效,血栓栓塞和出血发生率均低于全国质量数据库报告的平均水平。

研究设计与样本

  • 回顾性分析,社区医院,12年期间1936例腹腔镜袖状胃切除术患者。
  • 依诺肝素剂量按体重分层:<300磅30mg、300-400磅40mg、>400磅60mg,每12小时一次,术前至少2小时启动。

主要发现

  • 1936例患者中4例(0.21%)发生静脉血栓栓塞。
  • 3例(0.15%)发生出血并发症。

关键数值与推荐

  • 依诺肝素30mg每12小时用于体重<300磅患者。
  • 依诺肝素40mg每12小时用于体重300-400磅患者。
  • 依诺肝素60mg每12小时用于体重>400磅患者。
  • 方案于术前至少2小时启动。

临床怎么用

  • 对于接受腹腔镜袖状胃切除术的低风险患者,可考虑采用按体重分层的依诺肝素血栓预防方案。
  • 该方案在术前至少2小时启动,每12小时给药一次。

局限性

  • 回顾性研究设计。
  • 单中心社区医院数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: According to the most recent consensus guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS), almost all bariatric surgery patients are at least a moderate to high risk for the development of postoperative venous thromboembolism (VTE). The most recent update also concludes that there continues to be a lack of high-quality data on safety, efficacy, dosing, and duration of treatment for pharmacologic thromboprophylaxis in the perioperative period up to discharge. Observational data has reported VTE rate between 1.9 and 5.4% in patients undergoing bariatric surgery, and rates as low as 0.5% in less invasive surgery including laparoscopic sleeve gastrectomy (LSG). In a retrospective study of over 175,000 LSGs performed from 2015 to 2016, 0.6% were complicated by postoperative bleed. This retrospective analysis reviews results from a consistent low molecular weight heparin (LMWH) protocol over a 12-year period for safety and efficacy. OBJECTIVE: To address the lack of long-term data associated with a consistent LMWH protocol providing long-term safety and efficacy data in bariatric surgery. SETTING: The study was conducted at a Community Hospital, United States. METHODS: Protocol of enoxaparin 30 mg, 40 mg, or 60 mg every 12 h for patients with a weight of < 300 lbs., 300-400 lbs., or > 400 lbs., respectively, and is initiated at least 2 h before surgery. RESULTS: Of 1936 patients, 4 patients (0.21%) developed VTE while 3 patients (0.15%) had bleeding complications. CONCLUSION: The thromboprophylaxis regimen utilized in this study demonstrated enoxaparin to be safe and efficacious, with incidences of thromboembolism and bleeding both below reported averages from the national quality databases.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Dahman M, Ratermann C, Ghuniem L, et al. Longitudinal retrospective review of three-tiered low molecular weight heparin dosing protocol to prevent thromboembolism in low-risk patients undergoing laparoscopic sleeve gastrectomy. Surg Endosc. 2025. PMID: 40960540. doi:10.1007/s00464-025-12188-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。